Pharmaceuticals
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will...
2021-10-13 20:30
2321
Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week inShanghai (IBIWS) running from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote speech at the "2021 Future ...
2021-10-13 20:20
3110
DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing itsBiomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed ...
2021-10-12 22:52
2097
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
* Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors * Investment serves customers in addressing larger patient populations with new curative treatments * Enables suspension production of viral vectors up to...
2021-10-12 21:00
2404
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...
2021-10-12 20:30
1935
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle ce...
2021-10-12 20:23
2027
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produc...
2021-10-12 10:30
2101
EVERSANA™ named a Great Place to Work for third consecutive year in U.S.; earns valuable recognition in Canada, China and India
CHICAGO, Oct. 11, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, is celebrating its designation as aGreat Place to Work® by the global authority in workplace culture. Based on an anonymous survey to more than 3,000 EVERSANA...
2021-10-11 23:22
2728
Twist Alliance Pan-Cancer Methylation Panel Global Launch Event - A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy
GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally onSeptember 24th (U...
2021-10-11 21:00
2273
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres®Y-90 resin microspheres in China was successfully performed ...
2021-10-11 20:00
1601
Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities
- Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development and Manufac...
2021-10-11 16:50
2403
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences
2021-10-09 03:07
5143
CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
SUZHOU, China, Oct. 8, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the data on the preclini...
2021-10-08 08:00
3198
Breakthrough for medtech pioneer: Syntellix receives product approval for India, opening up fast-growing market with 1.38 billion people
Syntellix CEO Claassen: "Greatest and most important success in the company's history" - Indian CDSCO grants approvals for five MAGNEZIX® product families - The Era of Magnesium for orthopaedics and traumatology now also begins in India - Subcontinent will be the world's most populous growth m...
2021-10-07 22:08
2232
Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence at High Point, NC Facility
EAST RUTHERFORD, N.J., Oct. 7, 2021 /PRNewswire/ -- Cambrex today announced that it is expanding its manufacturing center of excellence inHigh Point, NC. The $30+ million investment is designed to meet the continually growing demand for small molecule development and manufacturing services. The ...
2021-10-07 20:30
2304
Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis
LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2021-10-07 06:00
1812
Luciole Pharmaceuticals and Cyclica Announce Research Collaboration to Accelerate Discovery of Novel Medicines
NATICK, Mass. and TORONTO, Oct. 7, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, a startup company focused on the discovery and development of small molecules that enhance the repair of oxidative damage to mitochondrial DNA (mtDNA), and Cyclica, the partner of choice for data-driven drug discovery...
2021-10-07 03:56
1353
ArisGlobal LifeSphere® MultiVigilance is selected by Asahi Kasei Pharma
MIAMI and TOKYO, Oct. 6, 2021 /PRNewswire/ -- Asahi Kasei Pharma Corp. has selectedLifeSphere® MultiVigilance as a new safety database with the purpose of building a system that supports efficiency, regulatory compliance, and global collaboration over the long term. In addition, Asahi Kasei Pharm...
2021-10-06 11:00
2109
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
ROSCREA, Ireland and FREIBURG, Germany, Oct. 5, 2021 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal ("GI") disorders, announced today that it has entered into a Licensing and C...
2021-10-05 20:10
2537
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...
2021-10-05 19:14
1196
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
